FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054867327> ?p ?o ?g. }

• W2054867327 endingPage "180" @default.
• W2054867327 startingPage "176" @default.
• W2054867327 abstract "Recent data suggest that differences in CA125 levels within the normal range may predict progression-free survival (PFS), but limited information is available regarding the value of these differences in predicting overall survival (OS) in patients with epithelial ovarian cancer. The objective of this study was to determine whether CA125 is an independent predictor of OS in patients with surgically defined disease status at the end of primary therapy prior to intraperitoneal (IP) consolidation chemotherapy. A secondary objective was to assess the relationship of CA125 level to PFS.Using data from a retrospective cohort of 433 patients who received intraperitoneal (IP) therapy following primary treatment for ovarian cancer between 1984 and 1998, we identified 241 patients with a complete clinical response and CA125 data at the time of second-look surgery prior to IP chemotherapy. Patient demographics and updated follow-up status were abstracted from medical records. Kaplan-Meier survival curves were compared using the log-rank test, and Cox regression models were used for multivariate analysis.The majority of patients had advanced stage III or IV disease (n=201, 83%) and high-grade histology (n=163, 68%). Taxane was used as part of primary platinum-based therapy in 56% (n=134) of patients, and subsequent IP chemotherapy was platinum-based in 85% (n=206). When considered as a continuous variable, CA125 was a predictor of OS (P=0.029). Using the median CA125 level in our study group as a cut-off, OS was increased in patients with CA125 < or =12 U/ml (median 5.8 years) compared with >12 (3.7 years) (P=0.0027). CA125 level was an independent predictor of OS (HR: 1.410; 95% CI, 1.044, 1.904, P=0.0248) in a multivariate model that included stage (P=0.0166), grade (P=0.0001), and findings at second-look surgery (P=0.0003). CA125 level was also a predictor of clinical PFS (radiographic or CA125 elevation criteria alone) in a subset of 161 patients as a continuous variable (P=0.0036), and when divided at the median (< or = or >12; median 2.8 years vs. 1.7 years; P=0.0017).In our study population, CA125 level at the end of primary therapy was a predictor of OS and PFS when considered as a continuous variable, or when divided at the median (< or = or >12 U/ml). Further prospective study is required to optimize clinically significant cut-off values within the normal range of CA125 levels for both OS and PFS endpoints." @default.
• W2054867327 created "2016-06-24" @default.
• W2054867327 creator A5001429608 @default.
• W2054867327 creator A5002011120 @default.
• W2054867327 creator A5016423289 @default.
• W2054867327 creator A5032196793 @default.
• W2054867327 creator A5034670220 @default.
• W2054867327 creator A5048186556 @default.
• W2054867327 creator A5052180720 @default.
• W2054867327 creator A5054602117 @default.
• W2054867327 creator A5073323475 @default.
• W2054867327 creator A5086908552 @default.
• W2054867327 creator A5090740287 @default.
• W2054867327 date "2007-01-01" @default.
• W2054867327 modified "2023-09-24" @default.
• W2054867327 title "CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy" @default.
• W2054867327 cites W1849884743 @default.
• W2054867327 cites W1965625577 @default.
• W2054867327 cites W1973522890 @default.
• W2054867327 cites W2010397777 @default.
• W2054867327 cites W2031145218 @default.
• W2054867327 cites W2093252833 @default.
• W2054867327 cites W2102282448 @default.
• W2054867327 cites W2103194390 @default.
• W2054867327 cites W2112230729 @default.
• W2054867327 cites W2121207995 @default.
• W2054867327 cites W2129940924 @default.
• W2054867327 cites W2154175915 @default.
• W2054867327 cites W2155481602 @default.
• W2054867327 cites W2165628351 @default.
• W2054867327 cites W2171753948 @default.
• W2054867327 cites W2556052768 @default.
• W2054867327 cites W4232699937 @default.
• W2054867327 cites W4293241248 @default.
• W2054867327 doi "https://doi.org/10.1016/j.ygyno.2006.07.027" @default.
• W2054867327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16996584" @default.
• W2054867327 hasPublicationYear "2007" @default.
• W2054867327 type Work @default.
• W2054867327 sameAs 2054867327 @default.
• W2054867327 citedByCount "65" @default.
• W2054867327 countsByYear W20548673272012 @default.
• W2054867327 countsByYear W20548673272013 @default.
• W2054867327 countsByYear W20548673272014 @default.
• W2054867327 countsByYear W20548673272015 @default.
• W2054867327 countsByYear W20548673272016 @default.
• W2054867327 countsByYear W20548673272017 @default.
• W2054867327 countsByYear W20548673272018 @default.
• W2054867327 countsByYear W20548673272019 @default.
• W2054867327 countsByYear W20548673272021 @default.
• W2054867327 countsByYear W20548673272022 @default.
• W2054867327 crossrefType "journal-article" @default.
• W2054867327 hasAuthorship W2054867327A5001429608 @default.
• W2054867327 hasAuthorship W2054867327A5002011120 @default.
• W2054867327 hasAuthorship W2054867327A5016423289 @default.
• W2054867327 hasAuthorship W2054867327A5032196793 @default.
• W2054867327 hasAuthorship W2054867327A5034670220 @default.
• W2054867327 hasAuthorship W2054867327A5048186556 @default.
• W2054867327 hasAuthorship W2054867327A5052180720 @default.
• W2054867327 hasAuthorship W2054867327A5054602117 @default.
• W2054867327 hasAuthorship W2054867327A5073323475 @default.
• W2054867327 hasAuthorship W2054867327A5086908552 @default.
• W2054867327 hasAuthorship W2054867327A5090740287 @default.
• W2054867327 hasConcept C10515644 @default.
• W2054867327 hasConcept C121608353 @default.
• W2054867327 hasConcept C126322002 @default.
• W2054867327 hasConcept C141071460 @default.
• W2054867327 hasConcept C143998085 @default.
• W2054867327 hasConcept C146357865 @default.
• W2054867327 hasConcept C151730666 @default.
• W2054867327 hasConcept C167135981 @default.
• W2054867327 hasConcept C2776694085 @default.
• W2054867327 hasConcept C2777511904 @default.
• W2054867327 hasConcept C2778239845 @default.
• W2054867327 hasConcept C2780427987 @default.
• W2054867327 hasConcept C2781451048 @default.
• W2054867327 hasConcept C38180746 @default.
• W2054867327 hasConcept C50382708 @default.
• W2054867327 hasConcept C530470458 @default.
• W2054867327 hasConcept C66339696 @default.
• W2054867327 hasConcept C71924100 @default.
• W2054867327 hasConcept C72563966 @default.
• W2054867327 hasConcept C86803240 @default.
• W2054867327 hasConceptScore W2054867327C10515644 @default.
• W2054867327 hasConceptScore W2054867327C121608353 @default.
• W2054867327 hasConceptScore W2054867327C126322002 @default.
• W2054867327 hasConceptScore W2054867327C141071460 @default.
• W2054867327 hasConceptScore W2054867327C143998085 @default.
• W2054867327 hasConceptScore W2054867327C146357865 @default.
• W2054867327 hasConceptScore W2054867327C151730666 @default.
• W2054867327 hasConceptScore W2054867327C167135981 @default.
• W2054867327 hasConceptScore W2054867327C2776694085 @default.
• W2054867327 hasConceptScore W2054867327C2777511904 @default.
• W2054867327 hasConceptScore W2054867327C2778239845 @default.
• W2054867327 hasConceptScore W2054867327C2780427987 @default.
• W2054867327 hasConceptScore W2054867327C2781451048 @default.
• W2054867327 hasConceptScore W2054867327C38180746 @default.
• W2054867327 hasConceptScore W2054867327C50382708 @default.
• W2054867327 hasConceptScore W2054867327C530470458 @default.

• next